Currently Viewing:
Currently Reading
AJMC® in the Press, January 3, 2020
January 03, 2020 – AJMC Staff
Review Finds Studies on Migraine and Caffeine Association Inconclusive
December 27, 2019 – Gianna Melillo
Top 5 Most-Read AJMC® Research Articles of 2019
December 26, 2019 – Christina Mattina
AJMC® in the Press, December 20, 2019
December 20, 2019 – AJMC Staff
Greek Researchers Outline New Consensus on Diagnosis and Treatment of Migraine
December 19, 2019 – Gianna Melillo
Low Sleep Efficiency Associated With Higher Odds of Migraine, Study Shows
December 18, 2019 – Matthew Gavidia
Tandem Gets FDA Clearance for Insulin Pump System With Novel Automated Dosing Feature
December 16, 2019 – Mary Caffrey
5 Findings From the December 2019 Issue of AJMC®
December 13, 2019 – Christina Mattina
AJMC® in the Press, December 13, 2019
December 13, 2019 – AJMC Staff

AJMC® in the Press, January 3, 2020

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An article written by Fox Business referenced a June 2019 contributor piece published on the website of The American Journal of Managed Care® (AJMC®). The contributor article, titled “The Deadly Costs of Insulin,” details the significant price increases of insulin treatment, which has seen insulin lispro, sold as Humalog, rise in cost by 1200% since 1996.

A study published in the December 2019 issue of AJMC®, “Cost-Sharing Payments for Out-of-Network Care in Commercially Insured Adults,” was highlighted in both the pulmonology and cardiology briefings of Physician’s Weekly for December 2019. The study analyzed claims among adults covered by employer-sponsored plans and found substantial variations in out-of-network cost-sharing payments.

A piece by US News & World Report highlighted another study from the December 2019 issue, “Benzodiazepine and Unhealthy Alcohol Use Among Adult Outpatients.” The study found that among outpatients who were screened for alcohol use, those with unhealthy alcohol use, women, and those who were older, white, and of lower socioeconomic status were more likely to use benzodiazepines, which include drugs such as diazepam (Valium), alprazolam (Xanax), and clonazepam (Klonopin).

Fox 5 DC’s article, “FDA approves new migraine drug,” cited a June 2018 study summary published in the Migraine compendium of AJMC®, “Study Summary: Costs Associated With Migraine in the United States.” The study was additionally spotlighted by Yahoo Finance and Healthcare Business News.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up